Reeteka Sud, Ph.D.
Affiliations: | 2005 | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Neuroscience BiologyGoogle:
"Reeteka Sud"Mean distance: 53433
Parents
Sign in to add mentor| Tracey A. Ignatowski | grad student | 2005 | SUNY Buffalo | |
| (Brain -derived tumor necrosis factor-alpha (TNF) mediates the antinociceptive effect of amitriptyline and modulates brain -body interactions during neuropathic pain.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sud R, Spengler RN, Nader ND, et al. (2008) Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes/macrophages from pro- to anti-inflammatory. European Journal of Pharmacology. 588: 217-31 |
| Spengler RN, Sud R, Knight PR, et al. (2007) Antinociception mediated by alpha(2)-adrenergic activation involves increasing tumor necrosis factor alpha (TNFalpha) expression and restoring TNFalpha and alpha(2)-adrenergic inhibition of norepinephrine release. Neuropharmacology. 52: 576-89 |
| Sud R, Ignatowski TA, Lo CP, et al. (2007) Uncovering molecular elements of brain-body communication during development and treatment of neuropathic pain. Brain, Behavior, and Immunity. 21: 112-24 |
| Reynolds JL, Ignatowski TA, Sud R, et al. (2005) An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience. 133: 519-31 |
| Ignatowski TA, Sud R, Reynolds JL, et al. (2005) The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-alpha (TNF). Neuropharmacology. 48: 448-60 |
| Reynolds JL, Ignatowski TA, Sud R, et al. (2004) Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. The Journal of Pharmacology and Experimental Therapeutics. 310: 1216-25 |